Akebia Therapeutics (AKBA) Share-based Compensation (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Share-based Compensation data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 67.72% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $12.8 million, a 67.9% increase from a year earlier, with the FY2025 full-year figure at $11.3 million, up 45.12% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.7 million, up from $3.2 million in the prior quarter.
• Over the last five years, Share-based Compensation for AKBA reached as high as $6.9 million in Q2 2022 and fell as low as $1.5 million in Q4 2023.
• Historically, Share-based Compensation has averaged $2.9 million across 5 years, with a median of $2.7 million in 2025.
• Across the five-year window, Share-based Compensation plunged 50.21% in 2023 and jumped 95.69% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3.0 million in 2022, then plunged by 50.21% to $1.5 million in 2023, then advanced by 12.09% to $1.7 million in 2024, then jumped by 88.51% to $3.2 million in 2025, then climbed by 14.66% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $3.7 million in Q1 2026, $3.2 million in Q4 2025, and $3.2 million in Q3 2025.